Rising R&D, Collaborations, and Partnerships Propel Innovation and Demand for Peptide Therapeutics

Peptide therapeutics market was valued at $45.5 million in 2024 and is projected to reach $121.6 million by 2035, growing at a CAGR of 9.4% during the forecast period (2025-2035). Increasing research and development (R&D) activity, collaborations, and partnerships are all significant contributors to boosting innovation and demand for peptide therapeutics. For instance, in July 2022, Eli Lilly Japan and Mitsubishi Tanabe Pharma Corp. (MTPC) entered into an agreement in Japan for the GIP/GLP-1 receptor agonist Tirzepatide. In this agreement, Eli Lilly Japan retains a manufacturing/marketing license for Tirzepatide, and MTPC will take responsibility for sales/distribution of the medicine.

Browse the full report description of “Peptide Therapeutics Market Size, Share & Trends Analysis Report by Route of Administration (Oral, and Parenteral), by Drug Type (Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, Teriparatide, Goserelin, Leuprorelin, and Other), and by Application (Obesity, Diabetes, Cancer, Infectious Diseases (Hepatitis), Gastrointestinal Disorders, Central Nervous System Disorders, Respiratory Disorders, and Others (AIDS, Personal Care and Cosmetics, and Other)) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/peptide-therapeutics-market

Key Players and Innovations

Several major players lead the peptide therapeutics market, including AstraZeneca Plc, Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, and Sanofi S.A. (Lantus). These companies are at the forefront of innovation by constantly advancing new technologies to meet the industry's evolving demand. These players assist in the market growth through the launch of new products, acquisitions, collaborations, and investments. For instance, in December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc., a global biotechnology company. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.

Market Coverage

• The market numbers available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035 

• Segment Covered- 

o By Route of Administration

o By Drug Type

o By Application 

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - AstraZeneca Plc, Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, Sanofi S.A. (Lantus), and others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Peptide Therapeutics Market Report Segment

By Route of Administration

• Oral
• Parenteral

By Drug Type 

• Dulaglutide
• Liraglutide
• Semaglutide
• Tirzepatide
• Teriparatide
• Goserelin
• Leuprorelin
• Other

By Application

• Obesity
• Diabetes
• Cancer
• Infectious Diseases (Hepatitis)
• Gastrointestinal Disorders
• Central Nervous System Disorders
• Respiratory Disorders
• Others (AIDS, Personal Care and Cosmetics, and Other)

Global Peptide Therapeutics Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/peptide-therapeutics-market